TY - JOUR T1 - Transbronchial cryobiopsy for diffuse parenchymal lung disease: 30- and 90-day mortality JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00337-2019 VL - 54 IS - 4 SP - 1900337 AU - Jasleen Pannu AU - Lance J. Roller AU - Fabien Maldonado AU - Robert J. Lentz AU - Heidi Chen AU - Otis B. Rickman Y1 - 2019/10/01 UR - http://erj.ersjournals.com/content/54/4/1900337.abstract N2 - Surgical lung biopsy (SLB) in diffuse parenchymal lung disease (DPLD) has been associated with significant in-hospital mortality (16% for non-elective patients, 1.7% for elective patients, overall 6.4%) [1, 2]. Overall 30-day mortality from SLB is reported at 1.5–4.5% from case series and 2.4% from a large European database [3]. Transbronchial cryobiopsy (TBC) has been proposed as a safer alternative to SLB for diagnosis of DPLD [4]. Existing studies on TBC report immediate procedural complications, but data on mortality at 30 and 90 days is sparse [2].This study suggests 30- and 90-day mortality after transbronchial cryobiopsy is higher than reported, confirming concerns raised about safety in advanced diffuse lung disease. Keen attention towards patient selection and procedural planning is warranted. http://bit.ly/2ySoZNq ER -